Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Month 18
Insurance companies can be strict about this
The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities Retatrutide May Redefine Multi-Receptor Therapeutics Triple agonism (GLP-1 + GIP + glucagon) isnt just about adding more receptors this distinct mechanism can boost energy expenditure, not just suppress appetite
These appointments also provide continued education, support, and accountability to help keep you engaged
Irwin N, OHarte FP, Gault VA, et al
For example, in a recent study, menopausal women with obesity or overweight lost more weight when tirzepatide was used along with HRT, and they had better cardiometabolic outcomes
US$ 27.54
US$ 25.00
US$ 25.69
US$ 20.94
US$ 26.43
US$ 27.11
US$ 27.69
